Bulletin
Investor Alert

Century Therapeutics Inc.

NAS: IPSC

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Nov 26, 2021, 4:13 p.m.

/zigman2/quotes/210490648/composite

$

17.20

Change

0.00 0.00%

Volume

Volume 1,610

Quotes are delayed by 20 min

/zigman2/quotes/210490648/composite

Previous close

$ 17.95

$ 17.20

Change

-0.75 -4.18%

Day low

Day high

$16.52

$19.87

Open

52 week low

52 week high

$16.29

$32.90

Open

Company Description

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It engages in harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi ...

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It engages in harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Valuation

Enterprise Value to EBITDA

-19.38

Efficiency

Liquidity

Current Ratio

6.51

Quick Ratio

6.51

Cash Ratio

6.32

Profitability

Return on Assets

-35.77

Return on Equity

-40.72

Return on Total Capital

-34.55

Return on Invested Capital

-37.67

Capital Structure

Total Debt to Total Equity

20.48

Total Debt to Total Capital

17.00

Total Debt to Total Assets

15.54

Long-Term Debt to Equity

20.25

Long-Term Debt to Total Capital

16.81

Officers and Executives

Name Age Officer Since Title
Mr. Joseph Jimenez 60 2019 Director

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
06/22/2021 Versant Venture Management LLC
100,000   Acquisition at $20 per share. 2,000,000
06/22/2021 Bayer AG
750,000   Acquisition at $20 per share. 15,000,000
06/22/2021 Eli Casdin
Director
750,000   Acquisition at $20 per share. 15,000,000
06/22/2021 Versant Venture Management LLC
614,095   Derivative/Non-derivative trans. at $0 per share. 0
06/22/2021 Versant Venture Management LLC
9,936,011   Derivative/Non-derivative trans. at $0 per share. 0
06/22/2021 Bayer AG
1,535,238   Derivative/Non-derivative trans. at $0 per share. 0
06/22/2021 Bayer AG
10,390,600   Derivative/Non-derivative trans. at $0 per share. 0
06/22/2021 FUJIFILM Holdings Corp.
3,974,404   Derivative/Non-derivative trans. at $0 per share. 0
06/22/2021 Eli Casdin
Director
2,456,380   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/ipsc

MarketWatch News on IPSC

  1. Century Therapeutics started at overweight with $40 stock price target at J.P. Morgan

    6:15 a.m. July 13, 2021

    - Tomi Kilgore

  2. Peter Thiel's Atai Life Sciences and 5 Other Companies List Shares

    4:19 p.m. June 18, 2021

    - Barron's Online

  3. Century Therapeutics sets IPO terms; to offer 10.6 mln shares priced at $18 to $20 each

    5:21 a.m. June 14, 2021

    - Ciara Linnane

/news/nonmarketwatch/company/us/ipsc

Other News on IPSC

  1. Meet members of the 2021 IPO class: oncology-focused biotechs

    11:00 a.m. Sept. 26, 2021

    - Seeking Alpha

  2. Century Therapeutics added to Russell 2000 Index

    3:08 p.m. Sept. 17, 2021

    - Seeking Alpha

  3. SYRS, BGRY and OPAD among mid-day movers

    11:21 a.m. Sept. 17, 2021

    - Seeking Alpha

  4. Century Therapeutics EPS misses by $1.53

    7:50 a.m. Aug. 12, 2021

    - Seeking Alpha

  5. Wall Street Breakfast:

    7:21 a.m. July 11, 2021

    - Seeking Alpha

  6. Century Therapeutics closes up 14% in its trading debut

    3:04 p.m. June 18, 2021

    - Seeking Alpha

  7. Century Therapeutics prices 10.6M-share IPO at $20

    11:07 p.m. June 17, 2021

    - Seeking Alpha

  8. Century Therapeutics Proposes $200 Million IPO

    12:49 p.m. June 16, 2021

    - Seeking Alpha

At a Glance

Century Therapeutics, Inc.

3675 Market Street

Philadelphia, Pennsylvania 19104

Phone

-

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

N/A

Net Income

$-53.58M

Employees

-

Trending Tickers
  • /zigman2/quotes/203240833/composite ASG-0.56%
  • /zigman2/quotes/200272047/composite OI-1.52%
  • /zigman2/quotes/201842100/composite DISCK-2.18%
  • /zigman2/quotes/208424563/composite GRFS-2.16%
  • /zigman2/quotes/202258849/composite COOP+2.03%
X
Powered by StockTwits
Link to MarketWatch's Slice.